Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.-论文-万方医学网

第一作者： Angus H,Forster

第一单位： Vaxxas Pty Ltd, Brisbane, Queensland, Australia.

作者： Angus H,Forster ^[1] ; Katey,Witham ^[1] ; Alexandra C I,Depelsenaire ^[1] ; Margaret,Veitch ^[2] ; James W,Wells ^[2] ; Adam,Wheatley ^[3] ; Melinda,Pryor ^[4] ; Jason D,Lickliter ^[5] ; Barbara,Francis ^[6] ; Steve,Rockman ^[7] ; Jesse,Bodle ^[8] ; Peter,Treasure ^[9] ; Julian,Hickling ^[10] ; Germain J P,Fernando ^[11]

作者单位： Vaxxas Pty Ltd, Brisbane, Queensland, Australia. ^[1] The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, TRI, Brisbane, Queensland, Australia. ^[2] Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. ^[3] 360biolabs, Melbourne, Victoria, Australia. ^[4] Nucleus Network Pty Ltd, Melbourne, Victoria, Australia. ^[5] Avance Clinical Pty Ltd, Thebarton, South Australia, Australia. ^[6] Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.;Seqirus Pty Ltd, Parkville, Victoria, Australia. ^[7] Seqirus Pty Ltd, Parkville, Victoria, Australia. ^[8] Peter Treasure Statistical Services Ltd, Kings Lynn, United Kingdom. ^[9] Working in Tandem Ltd, Cambridge, United Kingdom. ^[10] Vaxxas Pty Ltd, Brisbane, Queensland, Australia.;The University of Queensland, School of Chemistry & Molecular Biosciences, Faculty of Science, Brisbane, Queensland, Australia. ^[11]

医学主题词投药, 皮肤(Administration, Cutaneous);青少年(Adolescent);成年人(Adult);抗体, 病毒(Antibodies, Viral);澳大利亚(Australia);细胞, 培养的(Cells, Cultured);药物稳定性(Drug Stability);女(雌)性(Female);人类(Humans);免疫球蛋白A(Immunoglobulin A);流感病毒A型, H1N1亚型(Influenza A Virus, H1N1 Subtype);流感疫苗(Influenza Vaccines);流感, 人(Influenza, Human);注射, 肌肉内(Injections, Intramuscular);男(雄)性(Male);唾液(Saliva);T淋巴细胞(T-Lymphocytes);时间因素(Time Factors);经皮贴片(Transdermal Patch);治疗结果(Treatment Outcome);接种(Vaccination);青年人(Young Adult)

DOI 10.1371/journal.pmed.1003024

PMID 32181756

发布时间 2020-06-29

检索历史清除

Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.

PLoS medicine

相似文献

同项目论文

PLoS medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.

PLoS medicine

相似文献

同项目论文

PLoS medicine

相关期刊

检索历史清除